ARTICLE | Clinical News

Biota's vapendavir meets endpoint in Phase IIb rhinovirus trial

March 29, 2012 12:34 AM UTC

Biota Holdings Ltd. (ASX:BTA) said oral vapendavir twice daily for six days met the primary endpoint of reducing the severity of cold symptoms over days 2-4 after the onset of illness vs. placebo (p=0...